Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Patrick Oellers; Aaron Savar; Felipe Samaniego; Barbara Pro; Bita Esmaeli

doi:10.1097/IOP.0b013e31824ab228

Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Ophthalmic Plast Reconstr Surg. 2012 Nov-Dec;28(6):e145-6. doi: 10.1097/IOP.0b013e31824ab228.

Authors

Patrick Oellers¹, Aaron Savar, Felipe Samaniego, Barbara Pro, Bita Esmaeli

Affiliation

¹ Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

PMID: 22820440
DOI: 10.1097/IOP.0b013e31824ab228

Abstract

Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Conjunctival Neoplasms / diagnosis
Conjunctival Neoplasms / radiotherapy*
Drug Resistance, Neoplasm / drug effects
Fluorodeoxyglucose F18
Humans
Lymphoma, B-Cell, Marginal Zone / diagnosis
Lymphoma, B-Cell, Marginal Zone / radiotherapy*
Male
Positron-Emission Tomography
Rituximab
Treatment Outcome
Visual Acuity / physiology
Yttrium Radioisotopes / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Yttrium Radioisotopes
Fluorodeoxyglucose F18
Rituximab
ibritumomab tiuxetan